Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy?Zacks Investment Research • 02/28/25
MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead's Trodelvy® in Advanced Breast CancerBusiness Wire • 02/25/25
European Medicines Agency Validates Gilead's Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV PreventionBusiness Wire • 02/24/25
Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary CholangitisBusiness Wire • 02/20/25
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 02/20/25
U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority ReviewBusiness Wire • 02/18/25
Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?Zacks Investment Research • 02/17/25
Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy?Zacks Investment Research • 02/12/25
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 GuidanceZacks Investment Research • 02/12/25
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/12/25
Gilead Soars Into Buy Zone After Obliterating Fourth-Quarter ExpectationsInvestors Business Daily • 02/11/25